These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31029154)

  • 1. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
    Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
    Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer.
    Koido S; Taguchi J; Shimabuku M; Kan S; Bito T; Misawa T; Ito Z; Uchiyama K; Saruta M; Tsukinaga S; Suka M; Yanagisawa H; Sato N; Ohkusa T; Shimodaira S; Sugiyama H
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
    Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
    Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
    Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
    Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
    Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
    Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
    Takakura K; Koido S; Kan S; Yoshida K; Mori M; Hirano Y; Ito Z; Kobayashi H; Takami S; Matsumoto Y; Kajihara M; Misawa T; Okamoto M; Sugiyama H; Homma S; Ohkusa T; Tajiri H
    Anticancer Res; 2015 Jan; 35(1):555-62. PubMed ID: 25550602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
    Koido S; Okamoto M; Shimodaira S; Sugiyama H
    Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
    Tsukinaga S; Kajihara M; Takakura K; Ito Z; Kanai T; Saito K; Takami S; Kobayashi H; Matsumoto Y; Odahara S; Uchiyama K; Arakawa H; Okamoto M; Sugiyama H; Sumiyama K; Ohkusa T; Koido S
    World J Gastroenterol; 2015 Oct; 21(39):11168-78. PubMed ID: 26494971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial.
    Zhu X; Ju X; Cao F; Fang F; Qing S; Shen Y; Jia Z; Cao Y; Zhang H
    BMJ Open; 2016 Dec; 6(12):e013220. PubMed ID: 27909037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
    Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
    Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
    Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
    Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
    Kudo M; Moriguchi M; Numata K; Hidaka H; Tanaka H; Ikeda M; Kawazoe S; Ohkawa S; Sato Y; Kaneko S; Furuse J; Takeuchi M; Fang X; Date Y; Takeuchi M; Okusaka T
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):407-417. PubMed ID: 28497756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2021 Aug; 25(4):415-424. PubMed ID: 33886156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
    Ota S; Miyashita M; Yamagishi Y; Ogasawara M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5563-5572. PubMed ID: 34919493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 in the treatment of pancreatic cancer.
    Sudo K; Nakamura K; Yamaguchi T
    World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
    Yutani S; Komatsu N; Yoshitomi M; Matsueda S; Yonemoto K; Mine T; Noguchi M; Ishihara Y; Yamada A; Itoh K; Sasada T
    Oncol Rep; 2013 Sep; 30(3):1094-100. PubMed ID: 23784011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
    Ishikawa T; Kawashima H; Ohno E; Matsubara H; Sasaki Y; Achiwa K; Kanamori A; Sumi H; Hirai T; Nonogaki K; Tsuzuki T; Kuroiwa M; Hattori M; Maruta S; Hiramatsu T; Ando M; Hashimoto S; Hirooka Y
    Oncology; 2019; 96(1):1-7. PubMed ID: 30368509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.